Literature DB >> 17136984

Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD.

Donald A Mahler1, Joseph Ward, Gustavo Fierro-Carrion, Laurie A Waterman, Timothy F Lentine, Roberto Mejia-Alfaro, John C Baird.   

Abstract

In this study we developed self-administered versions of modified baseline and transition dyspnea indexes and compared the scores obtained by this method with the mean value obtained by two trained interviewers. Twenty-five patients (14 males/11 females) with chronic obstructive disease who had a chief complaint of "breathlessness" were tested. Age was 66+/-11 years; forced expiratory volume in one second was 48+/-23% predicted. The baseline total scores were 5.0+/-1.8 for the interviewers and 5.4+/-2.0 for the self-administered method. For the baseline dyspnea scores the correlations were 0.83 (p<0.0001) between self-administration and the mean value of two interviewers and 0.75 (p<0.0001) between the two interviewers. The transition total scores, obtained an average of 102 days (range, 7-377 days) later, were - 0.1+/-3.0 for the interviewers and - 0.4+/-3.0 for the self-administered method. For the transition dyspnea scores the correlations were 0.94 (p<0.0001) between self-administration and the mean value of two interviewers and 0.83 (p<0.0001) between the two interviewers. The self-administered dyspnea scores had similar correlations with measures of lung function as did the interview dyspnea scores. We conclude that self-administered versions of the modified baseline and transition dyspnea indexes provide comparable scores as those obtained by trained and experienced interviewers. The advantages of the self-administered versions include standardized methodology and computerized scoring.

Entities:  

Mesh:

Year:  2004        PMID: 17136984     DOI: 10.1081/copd-120030829

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  28 in total

1.  Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Ning Li; Ellen Goldmuntz; Lynette Keyes-Elstein; Ashley Pinckney; Daniel E Furst; Philip J Clements; Dinesh Khanna; Virginia Steen; Dean E Schraufnagel; Shiva Arami; Vivien Hsu; Michael D Roth; Robert M Elashoff; Keith M Sullivan
Journal:  Ann Rheum Dis       Date:  2018-11-08       Impact factor: 19.103

2.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

3.  Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Authors:  Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2018-11

4.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

5.  Design of the Redefining Therapy in Early COPD Study.

Authors:  MeiLan K Han; Wen Ye; Dong-Yun Kim; Prescott Woodruff
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

6.  Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Ning Li; Dinesh Khanna; Michael D Roth; Philip J Clements; Anna-Maria Hoffmann-Vold; Daniel E Furst; Grace Kim; Jonathan Goldin; Robert M Elashoff
Journal:  J Rheumatol       Date:  2019-02-15       Impact factor: 4.666

7.  Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.

Authors:  Donald P Tashkin; Elizabeth R Volkmann; Chi-Hong Tseng; Michael D Roth; Dinesh Khanna; Daniel E Furst; Philip J Clements; Arthur Theodore; Suzanne Kafaja; Grace Hyun Kim; Jonathan Goldin; Edgar Ariolla; Robert M Elashoff
Journal:  Chest       Date:  2016-12-22       Impact factor: 9.410

8.  Pilot Study of Self-care Breath Training Exercise for Reduction of Chronic Dyspnea.

Authors:  Gary Deng; Marc B Feinstein; Lara Benusis; Amy L Tin; Diane E Stover
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-01       Impact factor: 2.081

9.  Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12.

Authors:  J Yorke; S H Moosavi; C Shuldham; P W Jones
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

10.  Patient-reported dyspnea in COPD reliability and association with stage of disease.

Authors:  Donald A Mahler; Joseph Ward; Laurie A Waterman; Corliss McCusker; Richard ZuWallack; John C Baird
Journal:  Chest       Date:  2009-08-20       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.